Bispecific antibody–armed autologous T cells are bridged to SLAMF7 on target cells via elotuzumab and to CD3 on T cells via OKT3, forming an immune synapse and inducing T‑cell cytotoxicity (perforin/granzyme-mediated lysis) of SLAMF7+ cells.